Full-Time

Quality Engineer 1

Confirmed live in the last 24 hours

Natera

Natera

1,001-5,000 employees

Genetic testing and diagnostics solutions provider

Compensation Overview

$63k - $79k/yr

Mid

Company Historically Provides H1B Sponsorship

San Carlos, CA, USA

Hybrid role requiring 25-50% on-site work.

Category
QA & Testing
Manual Testing
Quality Assurance
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • B.S. or equivalent in science, engineering or related field
  • At least 2 years of experience in medical diagnostic, CLIA laboratory, or Life Sciences industry
  • Basic knowledge of CLIA/CAP regulations, ISO 13485 standard and/or FDA QSRs (21 CFR 820)
  • Computer skills (MS Word, Excel, PowerPoint, etc.)
  • Good technical writing and communication skills
  • Independent worker, a self-starter with strong organizational and planning skills
  • Ability to be productive and successful in an intense work environment
Responsibilities
  • Support internal and external audits (CLIA/CAP, ISO 13485, customer)
  • Support CAPA, Deviation, and Nonconformance investigation and reporting
  • Support Quality systems compliance to CLIA, FDA QSR, ISO 13485, and HIPAA
  • Participate in the management of Approved Suppliers
  • Follow established company standard operating procedures and good documentation practices
  • Review manufacturing/QC batch records
  • Other duties as assigned
Desired Qualifications
  • Demonstrated good judgment
  • Excellent attention to detail
  • Excellent written, verbal communication and interpersonal skills
  • Ability to be flexible and collaborate on multiple projects

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering personalized genetic counseling services alongside their testing, allowing patients to receive tailored guidance. The company's goal is to improve patient care through precise genetic insights.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Austin, Texas

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for non-invasive cancer monitoring boosts Natera's Signatera test adoption.
  • Telehealth expansion supports Natera's remote genetic counseling services.
  • Rising organ transplant procedures increase demand for Natera's Prospera test.

What critics are saying

  • Increased competition from companies like Lantheus may impact Natera's market share.
  • Natera's CFO selling stock could indicate potential internal concerns.
  • Reliance on insurance reimbursements poses a risk if healthcare policies change.

What makes Natera unique

  • Natera specializes in cell-free DNA testing for prenatal, oncology, and transplant health.
  • The company offers the unique Signatera test for personalized cancer monitoring.
  • Natera's Prospera Heart test uses a novel Donor Quantity Score for transplant rejection detection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

5%
Simply Wall St
Mar 13th, 2025
Natera (NasdaqGS:NTRA) Welcomes Former National Cancer Institute Director Back to Board

Last week, Natera (NasdaqGS:NTRA) announced a strategic expansion of its Board of Directors with the appointment of Monica Bertagnolli.

Investing.com
Mar 10th, 2025
Natera launches HEROES trial for breast cancer treatment

Natera launches HEROES trial for breast cancer treatment.

Financial Modeling Prep
Feb 28th, 2025
Lantheus Holdings, Inc. (NASDAQ:LNTH) Demonstrates Strong Capital Efficiency

Lantheus competes with other companies in the medical and pharmaceutical industries, such as ShockWave Medical, Medpace Holdings, LivaNova, Apellis Pharmaceuticals, and Natera.

BioSpace
Feb 19th, 2025
Natera To Report Its Fourth Quarter And Full Year Results On February 27, 2025

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m

MarketBeat
Nov 24th, 2024
Alpha DNA Investment Management LLC Invests $505,000 in Natera, Inc. (NASDAQ:NTRA)

Alpha DNA Investment Management LLC invests $505,000 in Natera, Inc. (NASDAQ:NTRA).